Myogenes Clozapine Test promises to improve outcomes for schizophrenia patients

FHS
October 4, 2024
11:34 am

Myogenes, a leading innovator in genetic testing, has been awarded a grant from Innovate UK, the UK’s innovation agency, to further develop its revolutionary Myogenes Clozapine Test for treatment-resistant schizophrenia (TRS). This cutting-edge genetic analysis tool promises to dramatically improve patient care and generate substantial cost savings for the NHS.

Treating Rural America: The telehealth solution

There is a persistent shortage of primary care doctors in the rural United States. Specialists, like OB-GYNs and endocrinologists, are even harder to access. According

November 2, 2023

Schizophrenia Sexual Dysfunction; Nuplazid Box Warning Tweak; Psych Practice Fraud?

Over half of people with schizophrenia experienced sexual dysfunction — 55.7% of men and 60% of women — according to a meta-analysis of more than

September 21, 2023

Vegetables, legumes, and seafood diet linked to lower heart risk in older men

Study reveals that a diet rich in vegetables, legumes, and seafood significantly reduces the risk of major adverse cardiovascular events in men over 75, compared

January 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.